SCHEMBL6977055

SCHEMBL6977055

CCCCSc1nc2ccc(S(=O)(=O)NC(C(CC)(CC)c3ccccc3)P(=O)(O)O)cc2s1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.42
LMNA P02545 3/20 0.42
MAPT P10636 3/20 0.42
PPARA Q07869 5/20 0.41
PPARG P37231 4/20 0.41
NPC1 O15118 2/20 0.40
HTT P42858 2/20 0.40
RAB9A P51151 2/20 0.40
ATM Q13315 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
RXFP1 Q9HBX9 1/20 0.38
PPARD Q03181 2/20 0.38
LDHA P00338 1/20 0.38
MEN1 O00255 1/20 0.38
CYP2C9 P11712 1/20 0.38
KMT2A Q03164 1/20 0.38
KDM4E B2RXH2 1/20 0.37
RECQL P46063 1/20 0.37
ALOX5 P09917 1/20 0.37
ALDH1A1 P00352 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5756885 0.82 MAPT (0.44) SMN1; SMN2LMNAMAPTPPARAPPARG
SCHEMBL5757042 0.79 PPARA (0.46) SMN1; SMN2LMNAMAPTPPARAPPARG
SCHEMBL5754971 0.76 ALOX15 (0.50) SMN1; SMN2PPARAPPARGHTTPPARD
SCHEMBL5756297 0.75 MAPT (0.46) SMN1; SMN2LMNAMAPTPPARAPPARG
SCHEMBL5755651 0.75 MEN1 (0.50) SMN1; SMN2LMNAMAPTPPARAPPARG
SCHEMBL5757695 0.75 POLB (0.51) SMN1; SMN2LMNAMAPTPPARAPPARG
SCHEMBL5756631 0.75 PPARG (0.50) SMN1; SMN2LMNAMAPTPPARAPPARG
SCHEMBL5753452 0.74 PPARG (0.51) SMN1; SMN2LMNAMAPTPPARAPPARG
SCHEMBL5756700 0.74 ALOX15 (0.49) SMN1; SMN2PPARAPPARGHTTPPARD
SCHEMBL5756888 0.73 MAPT (0.45) SMN1; SMN2LMNAMAPTPPARAPPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6548667-B2 For prevention and treatment of diseases caused by overexpression and overactivation of matrix metalloproteinase SAMSUNG ELECTRONICS CO. LTD. (KR) 2003-04-15 US disclosed
EP-1208092-A4 SULFONAMIDE DERIVATIVE AS A MATRIX METALLOPROTEINASE INHIBITOR SAMSUNG ELECTRONICS CO LTD (KR) 2003-01-02 EP disclosed
US-20020169314-A1 Sulfonamide derivative as a matrix metalloproteinase inhibitor SAMSUNG ELECTRONICS CO. LTD. (KR) 2002-11-14 US disclosed
EP-1208092-A1 SULFONAMIDE DERIVATIVE AS A MATRIX METALLOPROTEINASE INHIBITOR SAMSUNG ELECTRONICS CO., LTD. (KR) 2002-05-29 EP disclosed
WO-2001077092-A1 SULFONAMIDE DERIVATIVE AS A MATRIX METALLOPROTEINASE INHIBITOR SAMSUNG ELECTRONICS CO., LTD. (KR) 2001-10-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020169314-A1 Sulfonamide derivative as a matrix metalloproteinase inhibitor MMP9, MMP3, MMP14 SMN1; SMN2 654/4885LMNA 1839/4885MAPT 4046/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.